fda glp-1 warning september 2025 prescribing among teens with obesity What Patients Need to Know

June 2025: The European Medicines Agencys (EMAs) safety committee concluded that NAION is a very rare potential side effect of semaglutide medicines, like Wegovy

Diabetes contributes to structural and electrical changes in the heart, increasing susceptibility to arrhythmias

Some patients report feeling colder than usual whilst taking these medications, although this is not listed as an adverse effect in the Summary of Product Characteristics (SmPCs) for GLP-1 preparations in the UK

Medicare Coverage for GLP-1 Weight Loss Drugs: What You Need to Know Medicare Coverage for GLP-1 Weight Loss Drugs: What You Need to Know For years, Medicare beneficiaries heard the same frustrating answer: weight loss medications aren't covered